Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

Recruiting Phase 4 Interventional Study
Multiple Sclerosis Lower Urinary Track Symptoms
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
Atlantic Health System · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in fem…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Female patients with a diagnosis of multiple sclerosis 2. Age \> 18 3. Moderate to severe lower urinary tract symptoms as defined by an AUASS score \> 8 4. No UTI Exclusion Criteria: 1. Treatment with alpha-blocker, B3 agonist, or anticholinergic medication within the last …
Contacts

Mariah McKevitt, MD

973-971-7267

mariah.mckevitt@atlantichealth.org

CONTACT